This member resource of treatment guidelines includes anxiety and related disorders, bipolar disorder, depression, medication-induced movement disorders, schizophrenia, seizure disorders, sleep-wake disorders, and substance use disorders.
Searching for Solutions
AAPP opposes the SAMHSA policy change to prohibit the use of federal funds for the purchase of “fentanyl test strips or any other substance test kits intended for use by people using drugs.” Test strips are an essential component of overdose prevention interventions. Access AAPP’s Policy Statement “The funding and delivery of harm reduction services” to support your advocacy.
The Food and Drug Administration (FDA) approved the drug Auvelity this week for the treatment of agitation in adults with Alzheimer's dementia. The extended-release tablet is the first FDA-approved medication for this condition that is not an antipsychotic.
While there has been an increase in funding for and use of AI in health care in recent years, public opinion on AI’s role in providing accurate health information remains mixed.
AAPP has issued a statement opposing the Substance Abuse and Mental Health Services Administration’s (SAMHSA) policy change to prohibit the use of federal funds for the purchase of “fentanyl test strips or any other substance test kits, including xylazine and medetomidine test strips, intended for use by people using drugs.” Restricting access to this tool risks reversing progress in overdose prevention at a time when synthetic adulterants continue to drive morbidity and mortality.
Over a 5-year horizon, the treatment strategy initiating with paliperidone emerged as a favorable LAI option, providing the highest QALY gains at comparable or lower costs than the other LAI-initiating strategies.
This new proceedings of a workshop summarizes emerging scientific insights into brain-body communication pathways, and the implications for therapeutic development, public health, and overall well-being.
I was given the amazing opportunity to co-lead a platform presentation with Dr. Alexa Flood at the RX and Illicit Drug Summit (RX Summit) in Nashville. Through the support of the AAPP Ambassador Program, we were able to present to nearly 700 attendees and lead the second-most attended presentation of the conference.
No summary available
BPS received a petition to recognize Pharmacogenomics as a BPS specialty certification and has opened the public comment period. The comment period will close on June 3, 2026 at 5:00 PM ET.
No summary available
This paper is part of the Technical Assistance Coalition’s Refocus and Renew: Moving Towards Health series—a 10-paper collection guiding state leaders on SMI and SED treatment, recovery, and whole-person health.
In our newest member profile showcasing psychiatric pharmacist impact, learn how Dr. Jacky Parizher works as an outreach pharmacist providing low barrier treatment for opioid use disorder.
The findings of this study suggest no increased risk of long term adverse neurodevelopmental outcomes among children with prenatal exposure to buprenorphine versus methadone, further supporting buprenorphine as a safe treatment option for opioid use disorder during pregnancy.
Evidence suggests that the use of nicotine-containing e-cigarettes supports cigarette smoking cessation and reduction among individuals who smoke cigarettes regularly.
Joinpoint regression was used to examine mortality rates for opioid-only, opioids with a stimulant, opioids with benzodiazepines, among racial/gender groups to measure temporal trends in age-adjusted overdose mortality due to polysubstance-related overdose.
In this case series, researchers describe outpatient DTI outcomes.
This series of papers calls on state leaders to refocus on serious mental illness and serious emotional disturbances treatment and recovery and focuses on providing updated information and guidance on SMI and SED and renewing efforts for systems-level changes.
No summary available
The Substance Abuse and Mental Health Services Administration (SAMHSA) expanded its list of prohibited harm reduction services to exclude drug testing strips in new guidance documents. The updated guidance prohibits test kits that can be used to test for the presence of fentanyl or xylazine in drugs, which were explicitly allowed in a July letter.
In this cross-sectional study using contemporary data and methods, post-2018 Medicaid expansions were associated with substantial increases in buprenorphine treatment, particularly in high-need states operating under newer prescribing regulations.
A qualitative study of adults aged 65 and older in Southern California found that older medical cannabis users reported frequent and chronic use, widespread self-experimentation due to a lack of clinical guidance, and substitution of cannabis for other medications.
These results indicate the potential of PrR to capture gradual improvements in quality of life and reflect recovery progress.
A survey of U.S. behavioral health agency officials from every state and the District of Columbia.
Alcohol and drug addiction can cause many harms. This Research in Context feature looks at research into the causes of addiction and new ways to treat it.